Can personal stories heal the stigma of schizophrenia?

NCT ID NCT07708402

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a narrative therapy program designed to help people with schizophrenia reduce self-stigma. Twenty-four participants from halfway houses in northern Taiwan will attend four group and four individual sessions over eight weeks, using storytelling and workbook exercises. Researchers will analyze questionnaires and recordings to see if the program improves self-stigma, depression, social functioning, and well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a narrative therapy program using group and individual sessions to help people with schizophrenia explore personal experiences and reduce self-stigma
What this could lead to
If effective, this program could offer a new way to help people with schizophrenia feel less stigmatized and improve their well-being.
What could go wrong
This is a very small pilot study with only 24 participants, so results may not apply broadly. The program may not reduce stigma as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older. * Diagnosed with schizophrenia or schizoaffective disorder. * Clinically stable at the time of study enrollment. * Able to communicate in Mandarin Chinese or Taiwanese. * Able to read and write and complete study questionnaires. Exclusion Criteria: * Individuals who lack the capacity to provide informed consent. Decision-making capacity will be assessed using a 10-item true/false questionnaire adapted from Okoli et al. (2018). Participants who answer fewer than 7 questions correctly will be excluded. Those who answer 7 or more questions correctly will receive an additional explanation from the research team. Only individuals who demonstrate a complete understanding of the study after this explanation will be enrolled. * Unwilling to have the intervention sessions audio-recorded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.